The snow from the "bomb cyclone" may be done falling, but those snowflakes are being replaced by falling and freezing temperatures. Meteorologists Mace Michael and Dan Leonard join Cheddar to go over what to expect this weekend and how businesses are fairing in these temps.
Mace Michael reviews the freezing cold temps the East Coast will be experiencing this weekend. For areas like Boston which experienced significant coastal flooding from the precipitation, freezing temperatures will create even more problems.
Dan Leonard reviews how businesses are impacted when major weather like this occurs. Leonard says that restaurants experience less foot traffic but higher demand for delivery. He also anticipates streaming services and on-demand video demands to go up.
Leonard also explains how IBM Watson technology has improved their meteorology technology and weather analysis. Watson is able to predict and track storms two to three days out, which is critical to storm safety.
Blame geography for the U.S. getting hit by stronger, costlier, more varied and frequent extreme weather than anywhere on the planet, several experts said. But that's only part of it.
Residents across a wide swath of the U.S. raced Sunday to assess the destruction from fierce storms that spawned possibly dozens of tornadoes from the South and the Midwest into the Northeast.
The U.S. Food and Drug Administration has approved selling overdose antidote naloxone over-the-counter, marking the first time a opioid treatment drug will be available without a prescription.
Millions of Americans could lose access to Medicaid on April 1, and Joe Dunn, senior vice president of public policy at the National Association of Community Health Centers, joined Cheddar News' anchor Shannon LaNier to discuss what this means for public health.
One third of Americans don't have access to primary care providers in their communities, according to a study from the National Association of Community Health Centers published last month.
Neuralink, Elon Musk's brain implant venture, is reaching out to major U.S. neurosurgery centers to potentially begin testing its devices on humans, according to a Reuters report.
